- Home
- SGMT vs IGA Comparison
SGMT vs IGA Comparison
Compare SGMT & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- IGA
- Stock Information
- Founded
- SGMT 2006
- IGA 2005
- Country
- SGMT United States
- IGA United States
- Employees
- SGMT N/A
- IGA N/A
- Industry
- SGMT
- IGA Investment Managers
- Sector
- SGMT
- IGA Finance
- Exchange
- SGMT Nasdaq
- IGA Nasdaq
- Market Cap
- SGMT 128.5M
- IGA 147.1M
- IPO Year
- SGMT 2023
- IGA N/A
- Fundamental
- Price
- SGMT $3.72
- IGA $9.84
- Analyst Decision
- SGMT Strong Buy
- IGA
- Analyst Count
- SGMT 6
- IGA 0
- Target Price
- SGMT $25.67
- IGA N/A
- AVG Volume (30 Days)
- SGMT 315.0K
- IGA 42.3K
- Earning Date
- SGMT 03-12-2025
- IGA 01-01-0001
- Dividend Yield
- SGMT N/A
- IGA 8.93%
- EPS Growth
- SGMT N/A
- IGA N/A
- EPS
- SGMT N/A
- IGA N/A
- Revenue
- SGMT N/A
- IGA N/A
- Revenue This Year
- SGMT N/A
- IGA N/A
- Revenue Next Year
- SGMT N/A
- IGA N/A
- P/E Ratio
- SGMT N/A
- IGA N/A
- Revenue Growth
- SGMT N/A
- IGA N/A
- 52 Week Low
- SGMT $2.39
- IGA $7.77
- 52 Week High
- SGMT $7.38
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- SGMT 44.81
- IGA 60.40
- Support Level
- SGMT $3.70
- IGA $9.69
- Resistance Level
- SGMT $4.24
- IGA $9.84
- Average True Range (ATR)
- SGMT 0.23
- IGA 0.11
- MACD
- SGMT 0.04
- IGA 0.01
- Stochastic Oscillator
- SGMT 45.70
- IGA 99.95
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.